Gram-positive bacteria specific binding compounds

Patent metadata

Field	Value
Publication number	US-2016168232-A9
Application number	US-201313786206-A
Country	US
Kind code	A9
Filing date	Mar 5, 2013
Priority date	Jul 15, 2009
Publication date	Jun 16, 2016
Grant date	—

Abstract

The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

First claim

1 - 43 . (canceled)

44 . An antibody or functional part thereof capable of binding a serine-aspartate (SD) repeat-dependent epitope.

45 . The antibody of claim 44 , wherein the SD repeat epitope is a domain of an SD repeat (sdr) protein.

46 . The antibody of claim 45 , wherein the sdr protein is located on the surface of a bacterium.

47 . The antibody of claim 45 , wherein the sdr protein is anchored to the peptidoglycan cell wall of a gram-positive bacterium.

48 . The antibody of claim 47 , wherein the gram positive bacterium is a Staphylococcus species.

49 . The antibody of claim 48 , wherein the bacterium is S. aureus.

50 . The antibody of claim 49 , wherein the sdr protein is selected from the group consisting of C1fA (SdrA), C1fB (SdrB), SdrC, SdrD and SdrE.

51 . The antibody of claim 48 , wherein the bacterium is S. epidermidis.

52 . The antibody of claim 51 , wherein the sdr protein is selected from the group consisting of SdrF, SdrG and SdrH.

53 . The antibody of claim 48 , wherein the bacterium is S. saprophyticus.

54 . The antibody of claim 53 , wherein the sdr protein is SdrI.

55 . The antibody of claim 48 , wherein the bacterium is S. capitis.

56 . The antibody of claim 55 , wherein the sdr protein is SdrX.

57 . The antibody of claim 48 , wherein the bacterium is S. caprae.

58 . The antibody of claim 57 , wherein the sdr protein is selected from the group consisting of SdrY and SdrZ.

59 . The antibody of claim 44 , wherein the epitope comprises a molecule that binds to or is associated with an Sdr protein.

60 . The antibody of claim 59 , wherein the molecule that binds to or is associated with an Sdr protein is a component of a cell wall of a gram-positive bacteria.

61 . The antibody of claim 60 , wherein the molecule is peptidoglycan.

62 . The antibody of claim 60 , wherein the molecule is selected from the group consisting of peptides, proteins, sugars and sugar residues.

63 . The antibody of claim 44 , wherein the antibody or functional part thereof is coupled to another moiety to form an antibody-drug conjugates.

64 . The antibody of claim 61 , wherein said another moiety is a cytotoxic agent.

65 . The antibody of claim 62 , wherein the cytotoxic agent is an antibiotic.

66 . The antibody of claim 44 , wherein the antibody binds to cell wall lysates from S. aureus and/or S. epidermis.

67 . The antibody of claim 44 , wherein the antibody is able to compete with an antibody comprising
(a) a heavy chain CDR1 sequence RFAMS (SEQ ID NO:1), and (b) a heavy chain CDR2 sequence SINNGNNPYYARSVQY (SEQ ID NO:2) or SINSGNNPYYARSVQY (SEQ ID NO:60), and (c) a heavy chain CDR3 sequence DHPSSGWPTFDS (SEQ ID NO:3), and (d) a light chain CDR1 sequence RASENVGDWLA (SEQ ID NO:4), and (e) a light chain CDR2 sequence KTSILES (SEQ ID NO:5), and (f) a light chain CDR3 sequence QHYXRFPYT (SEQ ID NO:6), wherein X is I or M.

68 . The antibody of claim 67 , wherein the antibody binds to a Staphylococcus species selected from the group consisting of S. aureus, S. epidermidis, S. caprae, S. saprophyticus, S. capitis , or methicillin-resistant S. aureus (MRSA).

69 . A pharmaceutical composition comprising the antibody of claim 44 .

Assignees

• Genentech Inc
• Aimm Therapeutics Bv

Inventors

• Beaumont Tim
• Kwakkenbos Mark Jeroen
• Brown Eric J
• Morisaki John Hiroshi
• Hazenbos Wouter L W
• Mariathasan Sanjeev
• Kajihara Kimberly
• Xia Yi

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title